A. Larkin

648 total citations
12 papers, 554 citations indexed

About

A. Larkin is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, A. Larkin has authored 12 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 2 papers in Surgery. Recurrent topics in A. Larkin's work include Drug Transport and Resistance Mechanisms (7 papers), HER2/EGFR in Cancer Research (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). A. Larkin is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), HER2/EGFR in Cancer Research (3 papers) and Pancreatic and Hepatic Oncology Research (2 papers). A. Larkin collaborates with scholars based in Ireland, United States and Netherlands. A. Larkin's co-authors include Catherine A. Andrews, Donna J. Thuerauf, Christopher C. Glembotski, Patrick M. McDonough, Martin Clynes, Susan Kennedy, Lorraine O’Driscoll, John Crown, Robert O’Connor and E Morán and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and British Journal of Cancer.

In The Last Decade

A. Larkin

11 papers receiving 545 citations

Peers

A. Larkin

ONCOL

IMMUN

SURGE

Toshitake Hirai Japan

Yueping Sun China

Rehab Monir Samaka Egypt

Paula Costales Spain

Ying Di United Kingdom

Hyeong‐jun Han South Korea

Xuezhi Yang China

Shujun Yang China

Shan Cheng China

Toshitake Hirai Japan

A. Larkin

271 ×0.9

119 ×0.5

ONCOL

156 ×1.4

IMMUN

95 ×0.9

34 ×0.5

SURGE

Citations per year, relative to A. Larkin A. Larkin (= 1×) peers Toshitake Hirai

Countries citing papers authored by A. Larkin

Since Specialization

Citations

This map shows the geographic impact of A. Larkin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Larkin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Larkin more than expected).

Fields of papers citing papers by A. Larkin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Larkin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Larkin. The network helps show where A. Larkin may publish in the future.

Co-authorship network of co-authors of A. Larkin

This figure shows the co-authorship network connecting the top 25 collaborators of A. Larkin. A scholar is included among the top collaborators of A. Larkin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Larkin. A. Larkin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Eustace, Alex J., Sarah J. Kennedy, A. Larkin, et al.. (2011). Identification of predictive biomarkers for dasatinib treatment of metastatic melanoma.. Journal of Clinical Oncology. 29(15_suppl). 8578–8578.

Walsh, Naomi, Susan Kennedy, A. Larkin, et al.. (2010). Membrane transport proteins in human melanoma: associations with tumour aggressiveness and metastasis. British Journal of Cancer. 102(7). 1157–1162. 32 indexed citations

Eustace, Alex J., Sean P. Kennedy, John Crown, et al.. (2010). Targeting SRC kinase (SRC) in melanoma cells.. Journal of Clinical Oncology. 28(15_suppl). 8584–8584. 1 indexed citations

Roy, S, Elaine Kenny, Susan Kennedy, et al.. (2007). MDR1/P-glycoprotein and MRP-1 mRNA and protein expression in non-small cell lung cancer.. PubMed. 27(3A). 1325–30. 34 indexed citations

O’Driscoll, Lorraine, Naomi Walsh, A. Larkin, et al.. (2007). MDR1/P-glycoprotein and MRP-1 drug efflux pumps in pancreatic carcinoma.. PubMed. 27(4B). 2115–20. 52 indexed citations

O’Connor, Robert, Michael P. O’Leary, Conor D. Collins, et al.. (2006). A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 59(1). 79–87. 49 indexed citations

O’Driscoll, Lorraine, Susan Kennedy, Rachel Purcell, et al.. (2004). Expression and prognostic relevance of Mcl-1 in breast cancer.. PubMed. 24(2A). 473–82. 19 indexed citations

Morán, E, et al.. (2002). Methods for generation of monoclonal antibodies to the very small drug hapten, 5-benzimidazolecarboxylic acid. Journal of Immunological Methods. 271(1-2). 65–75. 13 indexed citations

Connolly, Lisa, E Morán, A. Larkin, et al.. (2001). A New Monoclonal Antibody, P2A8(6), that Specifically Recognizes a Novel Epitope on the Multidrug Resistance-Associated Protein 1 (MRP1), but not on MRP2 nor MRP3. PubMed. 20(5-6). 333–341. 6 indexed citations

10.

Larkin, A., et al.. (2000). p38 MAPK and NF-κB Collaborate to Induce Interleukin-6 Gene Expression and Release. Journal of Biological Chemistry. 275(31). 23814–23824. 306 indexed citations

11.

Morán, E, A. Larkin, Allan J. Masterson, et al.. (1997). Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42. European Journal of Cancer. 33(4). 652–660. 25 indexed citations

12.

Morán, E, A. Larkin, Gerard M. Doherty, et al.. (1997). A new mdr-1 encoded P-170 specific monoclonal antibody: (6/1C) on paraffin wax embedded tissue without pretreatment of sections.. Journal of Clinical Pathology. 50(6). 465–471. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact